Active, not recruitingPhase 2NCT04573920
Atrasentan in Patients With Proteinuric Glomerular Diseases
Studying Alport syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- Atrasentan(drug)
- Enrollment
- 103 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- Kidney Disease Medical Group, Glendale, California, United States
- Academic Medical Research Institute, Los Angeles, California, United States
- North America Research Institute, San Dimas, California, United States
- Stanford U School Of Medicine, Stanford, California, United States
- Colorado Kidney Care, Denver, Colorado, United States
- Northwest Louisiana Nephrology Research, Shreveport, Louisiana, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- Uni of Minnesota Hos and Clinics, Minneapolis, Minnesota, United States
- DaVita Clinical Research, Las Vegas, Nevada, United States
- Mountain Kidney And Hyper Associa, Asheville, North Carolina, United States
- Brookview Hills Research Assoc, Winston-Salem, North Carolina, United States
- Baylor Scott and White, Dallas, Texas, United States
- Prolato Clinical Research Center, Houston, Texas, United States
- Milwaukee Nephrologists SC, Wauwatosa, Wisconsin, United States
- Novartis Investigative Site, Gosford, New South Wales, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04573920 on ClinicalTrials.govOther trials for Alport syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07211685BAY3401016; Biomarker Study AlportBayer
- ACTIVE NOT RECRUITINGPHASE4NCT06499948Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients with Alport Syndrome (COMBINE-ALPORT)Stefan Lujinschi
- ACTIVE NOT RECRUITINGNCT06226896Effects of Dapagliflozin on Progression of Alport SyndromeNanjing University School of Medicine
- RECRUITINGNCT06526741ASF Alport Patient RegistryAlport Syndrome Foundation
- RECRUITINGNCT04947813Genotype-Phenotype Correlations in Patients With Alport SyndromeXinhua Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGNCT05927467Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)Institut National de la Santé Et de la Recherche Médicale, France
- RECRUITINGNCT02378805Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport SyndromeUniversity Hospital Goettingen